FilingReader Intelligence
Lupin launches generic eye drug in US market
July 16, 2025 at 10:19 AM UTC•By FilingReader AI
Lupin Limited has launched Loteprednol Etabonate Ophthalmic Suspension, 0.5%, in the United States. The product is bioequivalent to Lotemax Ophthalmic Suspension and treats steroid-responsive inflammatory conditions and post-operative eye inflammation.
The reference drug had estimated annual sales of $55m in the US as of May 2025.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
BSE:LUPIN•Bombay Stock Exchange
News Alerts
Get instant email alerts when Lupin publishes news
Free account required • Unsubscribe anytime